Quinone Reductase Inhibitor

Quinone Reductase Inhibitors (20):

Cat. No.	Product Name	Effect	Purity

HY-N0645

Dicoumarol	Inhibitor	99.89%
Dicoumarol is an inhibitor of both NAD(P)H:quinone oxidoreductase 1 (NQO1) and PDK1 with IC₅₀s of 0.37 and 19.42 μM, respectively.

HY-100367

ES 936	Inhibitor	98.66%
ES 936 is a potent and specific NQO1 inhibitor. ES 936 inhibits the growth of MIA PaCa-2 and BxPC-3 cells, with IC₅₀ values of 108 nM and 365 nM, respectively. ES936 significantly inhitbits the growth rate of MIA PaCa-2 xenograft tumors in mice. ES 936 can be used for the study of pancreatic cancer.

HY-174807

NPB-1575	Inhibitor
NPB-1575 is a potent, orally active and brain-penetrant anti-inflammatory agent. NPB-1575 mitigates neuroinflammation and resists ferroptosis by activating the IRS2/Nrf2/NF-κB axis. NPB-1575 shows protective effect against cerebral ischemic injury and improves the neurological functional prognosis. NPB-1575 can be used for the study of ischemic stroke.

HY-13543

Tretazicar	Inhibitor	99.65%
Tretazicar (CB 1954), an antitumor proagent, is highly selective against the Walker 256 rat tumour line. Tretazicar is enzymatically activated to generate a bifunctional agent, which can form DNA-DNA interstrand cross-links. Tretazicar in rat cells involves the reduction of its 4-nitro group to a 4-hydroxylamine by the enzyme NAD(P)H:quinone oxidoreductase 1 (NQO1).

HY-12346

FH1	Inhibitor	99.17%
FH1 (NSC 12407) is a NQO2 inhibitor with hepatoprotective effects. FH1 enhances hepatocyte function and promotes differentiation of induced pluripotent stem (iPS)-derived hepatocytes to a more mature phenotype and maturation of well-differentiated hepatocyte-like cell (iHeps) cultures. FH1 protects against Acetaminophen (HY-66005)-induced hepatotoxicity in both embryos and adult zebrafish.

HY-15673

KP372-1	Inhibitor	99.5%
KP372-1 is an Akt inhibitor that inhibits proliferation and induces apoptosis and anoikis. KP372-1 is also an NQO1 redox cycling agent that causes DNA damage (including DNA breakage) by generating ROS. KP372-1 can be used in cancer research (such as head and neck squamous cell carcinoma (HNSCC) and pancreatic cancer).

HY-N0606

Ginsenoside Rh3	Inhibitor	99.95%
Ginsenoside Rh3 is a bacterial metabolite of Ginsenoside Rg5. Ginsenoside Rh3 treatment in human retinal cells induces Nrf2 activation.

HY-108992

Deoxynyboquinone	Inhibitor	99.21%
Deoxynyboquinone, an excellent NQO1 substrate, is a potent antineoplastic agent. Deoxynyboquinone induces apoptosis in cancer cell lines. Deoxynyboquinone kills cancer cells through oxidative stress and reactive oxygen species (ROS) formation.

HY-N7335

Dehydroglyasperin C	Inhibitor	99.12%
Dehydroglyasperin C, a isoflavone, is a potent NAD(P)H:oxidoquinone reductase (NQO1) and phase 2 enzyme inducer. Dehydroglyasperin C has antioxidant, neuroprotective, cancer chemopreventive, and anti-inflammatory activities.

HY-118588

Diminutol	Inhibitor	98.1%
Diminutol is an inhibitor for NADP-dependent quinone oxidoreductase (NQO1), that is involved in microtubule morphogenesis and cell devision.

HY-170301

Keap1-IN-1	Inhibitor
Keap1-IN-1 (Compound 27) is the inhibitor for Keap1, that covalently modifys the Cys151 site in the BTB domain of KEAP1, and interfers with the interaction between Keap-Nrf. Keap1-IN-1 upregulates the mRNA expression of the antioxidant stress element (ARE)-dependent gene NQO1 with an EC₅₀ of 160 nM. Keap1-IN-1 exhibits cytotoxicity in cell U2OS with an EC₅₀ of 527 nM.

HY-171035

PRL-295	Inhibitor
PRL-295 is an orally active inhibitor targeting Keap1-Nrf2 interaction. PRL-295 increases the thermal stability of Keap1 and disrupts its interaction with Nrf2, thereby activating the Nrf2-dependent transcriptional target NAD(P)H:quinone oxidoreductase 1 (NQO1). PRL-295 protects against Acetaminophen (HY-66005)-induced liver injury in mice.

HY-RS09523

NQO1 Human Pre-designed siRNA Set A	Inhibitor
NQO1 Human Pre-designed siRNA Set A contains three designed siRNAs for NQO1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-170947

Antitumor agent-195	Inhibitor
Antitumor agent-195 (compound 16c) is a dual targeting agent of STAT3 and NQO1. Antitumor agent-195 significantly inhibits phosphorylation of STAT3 at Tyr705 at a concentration of 1 μM and effectively induce Apoptosis in MDAMB-231 and MDA-MB-468 breast cancer cells. Antitumor agent-195 as a NQO1 substrate strongly increases ROS generation and causes severe DNA damage in a dose-dependent manner. Antitumor agent-195 shows encouraging anti-tumor efficacy in the MDA-MB-231 xenograft model.

HY-169842

NSC 645827	Inhibitor
NSC 645827 is an inhibitor for NAD(P)H: quinone oxidoreductase 1 (NQO1) with an IC₅₀ of 0.7 μM.

HY-RS22982

Nqo1 Rat Pre-designed siRNA Set A	Inhibitor
Nqo1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Nqo1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS16549

Nqo1 Mouse Pre-designed siRNA Set A	Inhibitor
Nqo1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Nqo1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-N14947

Pterulinic acid	Inhibitor
Pterulinic acid is a coenzyme I: Coenzyme Q oxidoreductase inhibitor. he IC₅₀ (μg/mL) L1210 and HL60 of Pterulinic acid to mammalian cell lines are 50 and 20 respectively. HeLaS3 25; BHK is 100.

HY-N14897

Pterulone	Inhibitor
Pterulone is a coenzyme I: Coenzyme Q oxidoreductase inhibitor found in fungus Pterula SP.82168.

HY-147548

Keap1-Nrf2-IN-10	Inhibitor
Keap1-Nrf2-IN-10 (compound 15) is a potent NQO1 inducer. Keap1-Nrf2-IN-10 inhibits oxidative stress by decreasing the levels of MDA, ROS, NQO1 in the liver for gamma-irradiated mice. Keap1-Nrf2-IN-10 improves the survival of gamma-irradiated mice.

Name
Email *

	Sorry, but the email address you supplied was invalid.